ChiCTR-TRC-08000115: Multicenter, double-blinding, randomized controlled, phase II clinical trial on combined chemotherapy of Endostar (Recombinant Human Endostatin) for untreated patients with advanced melanoma |
|
|
| Completed | 1 | 140 | | Endostar combined with dacarbazine (add a drug that inhibits neovascularization to chemotherapy) ;Dacarbazine combined with placebo | Expert Committee for Melanoma of CSCO; Melanoma Experts Committee of Chinese Society of Clinical Oncology, Self-financing | Advanced melanoma | | | | |
NCT00600496: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) |
|
|
| Active, not recruiting | 1 | 140 | US | AZD6244, ARRY-142886, Dacarbazine, Erlotinib, Docetaxel, Taxotere®, Temsirolimus | AstraZeneca | Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer | 08/10 | 12/24 | | |
NCT03761095: A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) |
|
|
| Completed | 1 | 41 | US | Unesbulin, PTC596, Dacarbazine, DTIC | PTC Therapeutics | Leiomyosarcoma | 02/24 | 02/24 | | |
